SCHEDULE: North Peak Capital Discloses 5.1% Stake in Haemonetics

North Peak Capital Management, LLC and affiliated entities have reported a 5.1% beneficial ownership stake in Haemonetics Corporation, totaling 2,370,495 shares.

Summary

• North Peak Capital Management, LLC, along with its affiliated funds (North Peak Capital Partners, LP, North Peak Capital Partners II, LP, North Peak Capital Alpha Fund, LP, and North Peak Capital Ultra Fund, LP), and individuals Jeremy S. Kahan and Michael K. Kahan, have filed a Schedule 13G.
• North Peak Capital Management, LLC beneficially owns an aggregate of 2,370,495 shares of Haemonetics Corporation common stock, representing 5.1% of the class.
• North Peak Capital GP, LLC, Michael Kevin Kahan, and Jeremy Steven Kahan each beneficially own 1,882,037 shares, representing 4.0% of the class.
• The ownership percentages are based on 46,471,350 shares of Haemonetics Common Stock outstanding as of January 30, 2026, as disclosed in the Issuer's Form 10-Q filed on February 5, 2026.
• The reporting persons disclaim beneficial ownership of shares held by other reporting persons and state that the securities were not acquired for the purpose of changing or influencing control, except for activities solely related to a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake can lend credibility and potentially attract further investment, despite the passive nature of the filing.

Positives

• A significant institutional investor, North Peak Capital Management, LLC, has taken a 5.1% stake in Haemonetics Corporation, indicating confidence in the company's long-term prospects.
• The filing is a passive 13G, suggesting the investment is not currently intended to influence control, which can be viewed as a stable, long-term commitment.

Negatives

• The 'other than activities solely in connection with a nomination under §§ 240.14a-11' clause, while standard for passive 13G filers, could signal potential for future shareholder activism if performance does not meet expectations.

Risks

• Potential for future shareholder activism: Although the filing is a passive 13G, the explicit mention of 'activities solely in connection with a nomination under §§ 240.14a-11' suggests that North Peak Capital could, in the future, seek to nominate directors to the board, potentially leading to governance challenges or strategic shifts.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G often signal a vote of confidence in a company's valuation or strategic direction. For Haemonetics, a medical technology company, a significant stake by an investment firm like North Peak Capital could attract further institutional interest, potentially impacting its stock performance relative to peers in the medical device or blood management solutions sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by North Peak Capital Management, LLC could be viewed positively, potentially increasing investor confidence and attracting further institutional interest in Haemonetics Corporation.

Key Dates

Recommendation

The filing indicates a significant institutional stake by North Peak Capital, which is generally a positive signal of confidence. However, as a passive 13G, it doesn't suggest immediate catalysts for substantial price movement. The clause regarding potential nominations under Rule 14a-11 introduces a minor element of uncertainty regarding future activism, but for now, a 'hold' recommendation is appropriate as investors await further developments or operational updates from Haemonetics.

Keywords

Haemonetics Corporation, HAE, North Peak Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investment, Shareholder Stake, Investment Adviser, Common Stock